v3.26.1
Segment Reporting
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The following table presents selected financial information with respect to the Company’s single operating segment for the three months ended March 31, 2026 and 2025 (in thousands):
Three Months Ended March 31,
20262025
Revenue:
Collaboration and license revenue$— $400 
Grant revenue78 700 
Total revenue78 1,100 
Less:
Operating expenses:
Descartes-08 for MG12,135 7,036 
Descartes-08 for dermatomyositis
227 — 
Early stage programs355 990 
Research and development employee expenses3,828 3,702 
Research and development stock-based compensation expense949 1,275 
Research and development facilities and other expenses1,969 1,671 
General and administrative7,114 8,315 
Other expense (income), net (1)
12,683 (4,179)
Net loss$(39,182)$(17,710)
(1) Includes interest income; gain on change in fair value of warrant liabilities; (loss) gain on change in fair value of contingent value right liability; and other expense, net.